JPT Peptide Technologies GmbH is a leading provider of innovative peptide-based services, and catalog products & kits, as well as a research and development partner for projects in Immunology, Proteomics and Drug Discovery.
JPT's head office and production sites are located in Berlin, Germany. All of its production and services are performed in Berlin/ Germany in accordance with DIN EN ISO 9001:2015 guidelines.
Together with its partner company JPT Peptide Technologies Inc. based in Acton, near Boston, Massachusetts, JPT is serving a worldwide customer base in the pharmaceutical and biotechnology industries, as well as researchers in universities, governmental and non-profit organizations. Over the past decade, JPT has developed a portfolio of proprietary technologies and a series of unique products and services which support research efforts in proteomics, all development phases of novel vaccines or immunotherapies and peptides based drug discovery.
|2004||JPT Peptide Technologies GmbH was established as a spin-off of Jerini AG, a Berlin based peptide drug discovery company.
DIN ISO 9001:2000 Certification
|2008||JPT became a wholly owned subsidiary of BioNTech AG, Mainz (Germany), a company that develops novel immune therapy and diagnostic approaches for various cancers. GCLP Compliance Audits (NIH, IAVI, BCM, Cellmedica, Genticel, Karolinska)|
|2009||JPT is actively involved in R&D partnerships and contract research projects focusing on seromarker discovery & validation, development of immune monitoring tools and diagnostics, vaccine target discovery, peptide lead identification & optimization, biomarker quantification by targeted proteomics, enzyme substrate identification & sensitivity profiling.|
|2010||DIN ISO 9001:2008 Certification|
|2011||JPT launched an online shop to ease the access to its unique portfolio of catalog peptide microarrays, peptide pools and intelligent peptide collections.|
|2012||JPT's HIV microarrays and cyclic peptides used for analysis of HIV Vaccine Trial RV144 (Karasavvas et al., AIDS Res Hum Retroviruses, 2012)|
|2013||JPT conducts first its hands-on workshop: Microarray Application Training.|
|2014||JPT's peptide technologies are successfully used in various clinical immunotherapy developments.
JPT's scientists and technologies helped to decipher the Human Proteome (Wilhelm et al., Nature, 2014).
We celebrate our 10th anniversary.
|2015||JPT completes its product and service portfolio for all developments phases of immunotherapies and vaccines ranging from deep target and epitope discovery to clinical applications.
JPT starts work to create the largest repository of peptides consisting of > 1 Mio peptides for MS-based proteomics (ProteomeTools project).
|2016||DIN ISO 9001:2015 Certification
JPT expands its peptide capacities for applications in cellular therapy and clinical immune monitoring.
We launched The Human Proteome Peptide Catalog, the most comprehensive resource for validated human reference peptides.
|2019||JPT turned 15 and celebrated with a party. We launched the PepSup™ Cell Activation Kit and were featured in the film "30 years after the wall".|
|2020||Our PepMixes™ and Clinical Grade Peptides were successfully applied in the development of several leading COVID-19 vaccines. We are very proud of this! We were able to keep SARS-CoV-2 out of JPT facilities and prevent its spread among our staff.|